**Supplemental Figure S1.** Shows (A) least squares (LS) mean (± standard error [SE]) summed pain intensity difference for SPID0-6 and SPID18-24, and (B) LS mean (± SE) time-weighted pain relief scores for TOTPAR0-6 and TOTPAR18-24. During both intervals, all active treatments were statistically superior to placebo, and meloxicam IV 30 mg and 60 mg were statistically superior to morphine. *P < 0.001 vs placebo; †P = 0.008 vs morphine; ‡P = 0.011 vs morphine; §§P = 0.029 vs morphine; ¶P < 0.001 vs morphine; ††P = 0.018 vs morphine; ‡‡P = 0.004 vs morphine; *P = 0.008 vs morphine. Abbreviation: IV, intravenous.
*P < 0.001 vs placebo; †P = 0.008 vs morphine; ‡P = 0.011 vs morphine; §P = 0.029 vs morphine; ¶P < 0.001 vs morphine; ‡P = 0.018 vs morphine; §P = 0.004 vs morphine; *P = 0.008 vs morphine.

Abbreviation: IV, intravenous.